Last reviewed · How we verify

depot naltrexone

New York State Psychiatric Institute · FDA-approved active Small molecule Quality 5/100

depot naltrexone is a Small molecule drug developed by New York State Psychiatric Institute. It is currently FDA-approved. Also known as: Vivitrol, Depotrex.

At a glance

Generic namedepot naltrexone
Also known asVivitrol, Depotrex
SponsorNew York State Psychiatric Institute
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about depot naltrexone

What is depot naltrexone?

depot naltrexone is a Small molecule drug developed by New York State Psychiatric Institute.

Who makes depot naltrexone?

depot naltrexone is developed and marketed by New York State Psychiatric Institute (see full New York State Psychiatric Institute pipeline at /company/new-york-state-psychiatric-institute).

Is depot naltrexone also known as anything else?

depot naltrexone is also known as Vivitrol, Depotrex.

What development phase is depot naltrexone in?

depot naltrexone is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing